iodofiltic acid has been researched along with Scleroderma, Systemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kawano, H; Kudo, T; Maemura, K | 1 |
| Doi, S; Ishizaki, Y; Kawahata, K; Kawasaki, T; Kiyokawa, T; Mizushima, M; Ooka, S; Sakurai, K; Takakuwa, Y; Tonooka, K | 1 |
| Hanaoka, H; Iida, H; Kawahata, K; Kiyokawa, T; Nakajima, Y; Okada, Y; Okazaki, T; Ozaki, S; Takakuwa, Y; Yamada, H; Yamaguchi, K | 1 |
3 other study(ies) available for iodofiltic acid and Scleroderma, Systemic
| Article | Year |
|---|---|
Topics: Aged; Fatty Acids; Female; Humans; Iodine Radioisotopes; Iodobenzenes; Japan; Middle Aged; Myocardial Perfusion Imaging; Nicorandil; Scleroderma, Systemic; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2020 |
Treatment of myocardial fibrosis in systemic sclerosis with tocilizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cardiomyopathies; Fatty Acids; Female; Fibrosis; Humans; Iodobenzenes; Mycophenolic Acid; Myocardium; Scleroderma, Systemic | 2021 |
A low perfusion-metabolic mismatch in
Topics: Aged; Asymptomatic Diseases; Cause of Death; Coronary Circulation; Disease Progression; Echocardiography; Fatty Acids; Female; Fibrosis; Heart Diseases; Humans; Iodine Radioisotopes; Iodobenzenes; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Scleroderma, Systemic; Thallium | 2019 |